Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IMTX | US
-0.08
-0.68%
Healthcare
Biotechnology
31/03/2024
05/07/2024
11.74
11.73
11.78
11.50
Immatics N.V. a clinical-stage biopharmaceutical company focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors which is in Phase 1b clinical trial; IMA203CD8 a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma which is in preclinical stage; and IMA30x an allogenic cellular therapy product candidate which is in preclinical stage. The company also develops TCR Bispecifics products including IMA401 which is in Phase 1b clinical trial; and IMA402 and IMA403 which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen Germany.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Price Below SMA10D
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
23.7%1 month
39.6%3 months
58.7%6 months
53.1%-
-
4.52
0.08
0.05
-7.32
12.06
-
-84.19M
1.21B
1.21B
-
-44.50
-
209.00
-26.73
12.42
12.08
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.33
Range1M
2.44
Range3M
4.10
Rel. volume
0.33
Price X volume
1.69M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Verona Pharma plc | VRNA | Biotechnology | 16.11 | 1.31B | 2.55% | n/a | 22.79% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 61.44 | 1.29B | 1.02% | 39.55 | 68.66% |
Arcus Biosciences Inc | RCUS | Biotechnology | 14.12 | 1.28B | -1.67% | n/a | 1.56% |
Ardelyx Inc | ARDX | Biotechnology | 5.29 | 1.24B | -0.56% | n/a | 69.54% |
ARCUTIS BIOTHERAPEUTICS INC. | ARQT | Biotechnology | 10.49 | 1.21B | 9.27% | n/a | 91.91% |
Day One Biopharmaceuticals Inc. Common Stock | DAWN | Biotechnology | 13.71 | 1.20B | 1.56% | n/a | 0.10% |
NRIX | NRIX | Biotechnology | 19.47 | 1.19B | 0.31% | n/a | 17.28% |
IRON | IRON | Biotechnology | 46.62 | 1.15B | 4.93% | n/a | 0.60% |
Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 5.09 | 1.13B | -2.49% | n/a | 28.28% |
4D Molecular Therapeutics Inc | FDMT | Biotechnology | 21.15 | 1.09B | 1.44% | n/a | 2.36% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 13.45 | 1.31B | -0.37% | n/a | 20.15% |
REV Group Inc | REVG | Recreational Vehicles | 24.74 | 1.28B | -2.06% | 5.86 | 66.74% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.36 | 1.14B | 1.60% | n/a | -628.58% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 17.73 | 799.13M | -2.42% | n/a | 4070.84% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 32.65 | 667.35M | -2.74% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -7.32 | -2.43 | Cheaper |
Ent. to Revenue | 12.06 | 4,101.76 | Cheaper |
PE Ratio | - | 41.26 | - |
Price to Book | 4.52 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 58.67 | 76.52 | Lower Risk |
Debt to Equity | 0.08 | 0.51 | Cheaper |
Debt to Assets | 0.05 | 0.24 | Cheaper |
Market Cap | 1.21B | 3.77B | Emerging |